Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

1. Casado, L.-F.
2. García-Gutiérrez, J.-V.
3. Massagué, I.
4. Giraldo, P.
5. Pérez-Encinas, M.
6. de Paz, R.
7. Martínez-López, J.
8. Bautista, G.
9. Osorio, S.
10. Requena, M.-J.
11. Palomera, L.
12. Peñarrubia, M.-J.
13. Calle, C.
14. Hernández-Rivas, J.-A.
15. Burgaleta, C.
16. Maestro, B.
17. García-Ormeña, N.
18. Steegmann, J.-L.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1002/CAM4.440 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus